About this trial
In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.
Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.
Eligibility criteria
Qualifiers
Patient must be able to read and sign the informed consent form
Stable prophylactic medication for 2 months prior to MRI
Patients diagnosed with migraine (with or without aura, episodic or chronic). Diagnosis is ensured by clinical interview (at least 8 weeks prior to MRI). Also, patients complete a migraine questionnaire (HARDSHIP) (at least 8 weeks before MRI). Migraine frequency ≥ 2 migraine attacks/month.
Patients with drug resistent epilepsy accroding to ILAE crtieria
Disqualifiers
Treatment of migraine disease with Botox within < 4 months before baseline and during the study period
Pregnant or breastfeeding women
Intention during the course of the trial to become pregnant
Women with bilateral ovariectomy, with or without hysterectomy, and postmenopausal women (>2 years of age) are not considered childbearing.
Trial design
Treatments tested in this trial
- Structural MRI
- Quantitative MRI
- Diffusion MRI
- fMRI
- MR Spectroscopy
Treatment groups
Sponsors and collaborators
University of Zurich
Lead sponsor
Balgrist University Hospital
Collaborator